We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca’s Drug Candidate for a Rare Genetic Disease Shows Promise in Late-Stage Trial
AstraZeneca’s Drug Candidate for a Rare Genetic Disease Shows Promise in Late-Stage Trial
AstraZeneca (AZ) said that its once-daily oral investigational drug, ALXN1840, performed well in phase 3 clinical trial for patients with Wilson disease, a rare, genetic condition, removing excess copper from tissues approximately three times more effectively than standard of care treatments.